Key Developments: Actavis PLC (ACT)

ACT on New York Consolidated

304.76USD
30 Mar 2015
Change (% chg)

$1.20 (+0.40%)
Prev Close
$303.56
Open
$307.82
Day's High
$307.82
Day's Low
$304.10
Volume
2,298,756
Avg. Vol
3,221,934
52-wk High
$317.72
52-wk Low
$184.71

Search Stocks

Latest Key Developments (Source: Significant Developments)

Actavis PLC's Amneal Pharmaceuticals Pty Ltd signs deal to acquire generic business of Actavis Australia Pty Ltd
Monday, 30 Mar 2015 08:34pm EDT 

Actavis PLC:Says that Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, subsidiary of Actavis plc announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis' in-country generic pharmaceuticals business for an agreed price.Financial terms of the agreement are not available.However, both sides have agreed to work expeditiously to complete transaction with the goal of preventing disruption of supply to existing purchasers of Actavis' products.  Full Article

Actavis PLC completes Allergan acquisition
Tuesday, 17 Mar 2015 09:00am EDT 

Actavis PLC:Has completed acquisition of Allergan Inc in cash and equity transaction valued at about $70.5 bln.Combination creates one of world's top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 bln anticipated in 2015.  Full Article

Actavis PLC receives FDA approval for VIIBRYD (vilazodone HCl) 20mg once daily as a therapeutic dose
Monday, 16 Mar 2015 04:05pm EDT 

Actavis PLC:Says U.S. Food and Drug Administration (FDA) has approved a lower therapeutic dose of VIIBRYD (vilazodone HCl) (20mg) to accompany the 40 mg daily therapeutic dose.This supplemental new drug application (sNDA) approval for VIIBRYD expands dosing options available to health care providers when using VIIBRYD to treat their adult patients with MDD.VIIBRYD 20mg therapeutic dose is now available in pharmacies.  Full Article

Actavis PLC receives FDA approval of SAPHRIS
Friday, 13 Mar 2015 08:00am EDT 

Actavis PLC:Says the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for SAPHRIS (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17).SAPHRIS is the only atypical antipsychotic treatment option with a sublingual (under the tongue) formulation.  Full Article

Actavis PLC confirms appeals Court grants injunction pending appeal related to Generic Pulmicort RESPULES
Thursday, 12 Mar 2015 05:00pm EDT 

Actavis PLC:Confirms that United States Court of Appeals for the Federal Circuit has granted AstraZeneca's request for injunction pending appeal preventing Actavis from further distribution of its generic version of Pulmicort RESPULES (budesonide inhalation suspension) 0.25, 0.5 mg.Under the ruling, Actavis' sales of generic Pulmicort have been enjoined pending the resolution of AstraZeneca's appeal before the Court.Court has set an expedited briefing schedule for the appeal, with expedited briefing to be concluded within 33 days.Injunction does not address product shipped prior to its issuance.Actavis' sales of generic Pulmicort had previously been enjoined under a temporary injunction granted by the Appeals Court on Feb. 16.Appeals Court ruling followed the Feb. 13, 2015 launch of Actavis' product after the United States District Court for the District of New Jersey (i) found United States Patent No. 7,524,834 invalid, and (ii) denied AstraZeneca's request for a permanent injunction.  Full Article

Eli Lilly and Co loses Alimta drug patent case in Germany to Actavis - Reuters
Friday, 6 Mar 2015 09:39am EST 

Eli Lilly and Co:Has lost a patent case in Germany over its Alimta lung cancer drug to generic producer Actavis, hitting the company's future sales hopes for the medicine - Reuters.The German appeal court ruled that Actavis would not infringe patents held by Lilly if it marketed an alternative salt form of the drug, known generically as pemetrexed, once the compound patent expires in Dec 2015.The ruling contradicts a previous verdict by a lower court in Germany and Lilly's general counsel, Michael Harrington, said the company would fight the decision.  Full Article

Actavis PLC announces pricing of public offering of senior notes
Tuesday, 3 Mar 2015 08:20pm EST 

Actavis PLC:Announced that it has priced an offering of $21 billion aggregate principal amount of senior unsecured notes in 10 tranches in a registered public offering to be issued by its indirect wholly-owned subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries.The net proceeds from the offering of the Notes will be about $20.8 billion.Intends to use the net proceeds from the offering of the Notes, together with the proceeds from its offerings of its Ordinary Shares and 5.500 pct. Mandatory Convertible Preferred Shares, Series A and additional debt financing, including borrowings under unsecured term loan facilities.And an unsecured cash bridge loan facility, to finance a portion of the cash portion of the merger consideration for its previously announced acquisition of Allergan, Inc.Expects to use the net proceeds from the offering of the Notes, together with cash on hand, to redeem the Notes.J.P. Morgan, Mizuho Securities and Wells Fargo Securities are the joint book-running managers of the offering of the Notes.  Full Article

AstraZeneca PLC announces acquisition of rights to Actavis PLC portfolio
Tuesday, 3 Mar 2015 02:05am EST 

AstraZeneca PLC:Says that it has completed the transaction to acquire rights to Actavis' branded respiratory business in US and Canada.Says strategic transaction strengthens AstraZeneca's respiratory franchise globally and builds on acquisition of Almirall's respiratory portfolio in 2014 by extending company's development and commercialisation rights into US for both Tudorza Pressair and Duaklir Genuair.Says on completion of acquisition, AstraZeneca is paying Actavis $600 mln of initial consideration and agreed to pay low single digit royalties above a certain revenue threshold.AstraZeneca has also paid Actavis an additional $100 mln for a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between AstraZeneca and Actavis.  Full Article

Actavis PLC receives approval from European Commission for XYDALBA (dalbavancin)
Monday, 2 Mar 2015 08:30am EST 

Actavis PLC:Says European Commission has granted it's subsidiary Durata Therapeutics International B.V., marketing authorization for XYDALBA (dalbavancin) for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.Says XYDALBA is first and only once-weekly IV antibiotic approved for treatment of ABSSSI with two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes.  Full Article

Actavis PLC and Medicines360 announce FDA approval of LILETTA to prevent pregnancy for up to three years
Friday, 27 Feb 2015 08:00am EST 

Actavis PLC and Medicines360:Says approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years.LILETTA is placed in the uterus by a healthcare professional and works by continuously releasing levonorgestrel, a progestin, to prevent pregnancy.  Full Article

EU mergers and takeovers (March 17)

BRUSSELS, March 17 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Search Stocks